The GLP-1 analogs, semaglutide and liraglutide, delay the progression of atherosclerosis by regulating inflammatory pathways in low-density lipoprotein receptor-deficient (LDLr -/- ) and apolipoprotein E-deficient (ApoE -/- ) mice [16]
This is because it targets three different receptors and hormonesGLP-1, glucagon, and GIP (1)
Cagrilintide comes at appetite from the amylin side, a hormone pathway that the GLP-1 drugs barely touch
Prepare ahead: Keep your medication and supplies in one designated, easy-to-access spot
However, the potential for direct brain delivery through the olfactory pathway could provide unique appetite suppression benefits not achievable with injection alone
Research peptides exist in a different regulatory category than prescription medications, which is why they can be legally sourced in Canada while Retatrutide awaits Health Canada approval